Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching,...
Covered in this story
What has happened since
- Kodiak Sciences Inc is up 97.6% since this was published, 73 days ago.
- Palo Alto Networks is down 7.8% since this was published, 73 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Kodiak Sciences Inc
- H.C. Wainwright: $99.9 → $126 by Oct 2027 · Buy via Investing.com
- H.C. Wainwright: $89.9 → $58 by Sep 2027 · Buy via Investing.com
- Jefferies: $89.9 → $112 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KOD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kodiak Sciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.